卫宁健康(300253) - 2023 Q1 - 季度财报

Financial Performance - Total operating revenue for Q1 2023 was CNY 449,172,857.10, a slight increase from CNY 445,524,588.55 in Q1 2022, representing a growth of approximately 0.37%[6] - The company reported a net loss of ¥90,204,109.26 for the current period, compared to a net profit of ¥13,823,046.52 in the previous period[8] - Operating profit was recorded at -¥108,073,141.09, a significant decline from the previous operating profit of ¥23,204,986.50[8] - The net profit attributable to shareholders of the listed company is CNY -63,534,739.90, a decrease of 300.02% from CNY 31,763,439.87 in the previous year[22] - The total comprehensive income attributable to the parent company was -¥63,534,739.90, a decrease from ¥31,763,439.87 in the prior period[8] Operating Costs and Expenses - Total operating costs increased significantly to CNY 585,423,433.04 from CNY 460,944,963.89, marking an increase of about 27.0%[6] - Research and development expenses rose to CNY 94,566,268.35, up from CNY 66,198,838.64, reflecting a growth of approximately 42.9%[6] - The company's financial expenses increased by 62.16% compared to the same period last year, mainly due to a decrease in interest income[40] - The company's credit impairment losses increased by 61.85% year-on-year, reflecting a rise in bad debt provisions for accounts receivable[40] Assets and Liabilities - The total assets decreased to CNY 7,743,296,274.77 from CNY 7,821,828,010.96, a decline of about 1.0%[5] - Total liabilities decreased to CNY 2,652,001,850.22 from CNY 2,695,151,070.75, a reduction of approximately 1.6%[5] - The total liabilities and equity amounted to CNY 7,743,296,274.77, down from CNY 7,821,828,010.96, reflecting a decrease of approximately 1.0%[5] - The equity attributable to shareholders of the parent company increased slightly to CNY 5,119,636,812.60 from CNY 5,109,840,517.67, showing a growth of about 0.2%[5] Cash Flow - Cash flow from operating activities showed a net outflow of -¥92,026,081.61, improving from -¥98,677,812.85 in the previous period[12] - The company incurred a total cash outflow of ¥713,000,427.35 in operating activities, compared to ¥707,899,338.05 last year[12] - The net cash flow from operating activities is CNY -92,026,081.61, showing an improvement of 6.74% compared to CNY -98,677,812.85 in the same period last year[22] Revenue Breakdown - The revenue from the core medical health information business grew by 3.73%, while software sales and technical services revenue decreased by 1.62%[44] - The hardware sales revenue increased by 36.35% year-on-year[44] - The internet medical health business revenue declined by 12.73% year-on-year[44] - Total revenue from operating activities was ¥620,974,345.74, slightly up from ¥609,221,525.20 in the prior period[12] Investments and Projects - The company has completed the investment of CNY 49 million in the new generation smart medical product development and cloud service project, achieving 100% usage progress[54] - The company has confirmed CNY 712.46 million used in the new generation smart medical product development project in the first quarter of 2023[54] - The company has invested CNY 3,918.88 million in the drug supply chain management project, achieving a usage progress of 30.73%[54] - The company has allocated CNY 9.28651 million from the remaining fundraising for the drug supply chain management project to supplement working capital permanently[54] Shareholder Information - The company’s diluted earnings per share were reported at -¥0.0294, compared to ¥0.0148 in the previous period[8] - The company raised ¥2,940,000.00 from minority shareholders during the current period, consistent with the previous period[14] - The company’s major shareholders include Zhou Wei with 8.22% and Wang Ying with 4.96% of shares[46] - As of March 31, 2023, the company had repurchased 14,256,400 shares, representing 0.66% of the total share capital, with a total transaction amount of CNY 120.6238 million[54]